Vascular endothelial growth factor overexpression in myelodysplastic syndrome bone marrow cells: biological and clinical implications

Rosangela Invernizzi, Erica Travaglino, Matteo Giovanni Della Porta, Luca Malcovati, Anna Gallì, Raffaella Bastia, Mariella Ciola, Ilaria Ambaglio, Emanuela Boveri, Vittorio Rosti, Mario Cazzola

Research output: Contribution to journalArticlepeer-review

Abstract

In myelodysplastic syndrome (MDS), vascular endothelial growth factor (VEGF) may have regulatory effects on the hematopoietic system and contribute to disease progression. We analyzed by immunocytochemistry VEGF expression in bone marrow (BM) cells from 188 patients with MDS and 96 non-hemopathic subjects. We also measured VEGF BM plasma levels and in vitro VEGF release. Our aims were to evaluate whether VEGF expression abnormalities were associated with relevant laboratory or clinical findings and their possible prognostic value. In MDS, VEGF expression was higher than in controls (p < .0001) and VEGF release was significantly higher in the low-risk cases. A trend to a positive correlation between VEGF myeloid expression and apoptotic rate was observed. High myeloid VEGF levels were independently associated with longer overall survival (p < .0001) and progression-free survival (p = .0002). Our findings suggest that, in MDS, VEGF production and release may contribute to ineffective hematopoiesis, with a potential prognostic role.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalLeukemia and Lymphoma
DOIs
Publication statusAccepted/In press - Nov 29 2016

Keywords

  • bone marrow
  • myelodysplastic syndrome
  • prognosis
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Vascular endothelial growth factor overexpression in myelodysplastic syndrome bone marrow cells: biological and clinical implications'. Together they form a unique fingerprint.

Cite this